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Background: Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common inherited defect in
the mitochondrial fatty acid oxidation pathway, resulting in significant morbidity and mortality in undiagnosed
patients.
Newborn screening (NBS) has considerably improved MCADD outcome, but the risk of complication remains in
some patients. The aim of this study was to evaluate the relationship between genotype, biochemical parameters
and clinical data at diagnosis and during follow-up, in order to optimize monitoring of these patients.
Methods: We carried out a multicenter study in southwest Europe, of MCADD patients detected by NBS. Evaluated
NBS data included free carnitine (C0) and the acylcarnitines C8, C10, C10:1 together with C8/C2 and C8/C10 ratios,
clinical presentation parameters and genotype, in 45 patients. Follow-up data included C0 levels, duration of
carnitine supplementation and occurrence of metabolic crises.
Results: C8/C2 ratio and C8 were the most accurate biomarkers of MCADD in NBS. We found a high number of
patients homozygous for the prevalent c.985A > G mutation (75%). Moreover, in these patients C8, C8/C10 and
C8/C2 were higher than in patients with other genotypes, while median value of C0 was significantly lower (23
μmol/L vs 36 μmol/L).
The average follow-up period was 43 months. To keep carnitine levels within the normal range, carnitine
supplementation was required in 82% of patients, and for a longer period in patients homozygotes for the
c.985A>G mutation than in patients with other genotypes (average 31 vs 18 months). Even with treatment, median
C0 levels remained lower in homozygous patients than in those with other genotypes (14 μmol/L vs 22 μmol/L).
Two patients died and another three suffered a metabolic crisis, all of whom were homozygous for the c.985 A>G
mutation.
Conclusions: Our data show a direct association between homozygosity for c.985A>G and lower carnitine values at
diagnosis, and a higher dose of carnitine supplementation for maintenance within the normal range. This study
contributes to a better understanding of the relationship between genotype and phenotype in newborn patients
with MCADD detected through screening which could be useful in improving follow-up strategies and clinical
outcome.
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Medium-chain acyl-CoA dehydrogenase deficiency
(MCADD) is the most common inherited fatty acid β-
oxidation (FAO) defect and is a potentially fatal disorder.
FAO is a metabolic pathway of particular importance as
an energy source during fasting, when glucose supply be-
comes limited [1]. The overall incidence of MCADD, eval-
uated by tandem mass spectrometry (MS/MS) newborn
screening, is approximately 1:14600, which is 2- to 3-fold
higher than the incidence estimated by clinical diagnosis
[2]. Incidence varies widely by region, with a higher inci-
dence in the population of northern Europe [3,4].
The MCADD phenotype ranges from asymptomatic
[5] to Reye-like syndrome. Typical clinical presentation
consists of a metabolic crisis, characterized by hypoke-
totic hypoglycemia, lethargy, coma [6], seizures or sud-
den death [7], and triggered by catabolic stress during
fasting or illness. The disease usually manifests in the
first few years [8], although first presentation in adult-
hood has also been described [9]. Unusual manifesta-
tions, such as neonatal ventricular tachyarrhythmias
[10-12], pulmonary haemorrhage [10], and abnormal
motor behavior during sleep [13] have also been de-
scribed. There is a risk of neurological impairment after
an acute metabolic decompensation [8,14]. The long
term follow up of a Dutch cohort of clinically diagnosed
cases of MCADD identified disabilities in 21% of pa-
tients [15]. The mortality rate in the first 72 hours of
birth is 4%, with and additional mortality rate of 5-7% by
6 years of age in affected unscreened children [8,16].
Newborn screening (NBS) by MS/MS started in the
1990s. It has since been demonstrated to be accurate
and effective [2] with a clear benefit in countries with a
high percentage of Caucasians [17], contributing to a re-
duction in MCADD morbidity and mortality [18]. How-
ever, severe metabolic crises still occur, particularly in
the early post-natal period prior to NBS [8,19,20] and
before screening results are available [12,21]. Patients
with fatal neonatal presentation show low residual
MCAD enzyme activities (<1%) [22].
Elevations of octanoylcarnitine (C8), C8/C10 and C8/
C2 ratios are the most commonly reported markers in
screening for MCADD [23-26]. It is important to bear in
mind that C8 values are likely to be lower when screen-
ing samples are collected 72 h after birth [27]. C8/C10
and C8/C2 ratios does not seem to be affected by time
of sampling [4].
MCAD protein is encoded by the ACADM gene
(OMIM 607008), located on chromosome 1p31. More
than 80 mutations have been identified in this gene
(HGMD®), most of which are missense mutations. While
screening programs have greatly improved clinical out-
come and contributed to current understanding of
MCADD, several questions remain. Two of the mostimportant of these are how genotype and phenotype are
related [3,25,28] and the clinical relevance of novel vari-
ants of ACADM, as identified by newborn screening.
Approximately 80% of patients diagnosed clinically are
homozygous for the common c.985A>G mutation [25,29].
Patients diagnosed as a result of screening show a dif-
ferent mutational spectrum, with a lower proportion
(30-71%) of homozygotes for the common mutation
[3,20,21,23,25,27,30-35]. This diagnosis-dependent dif-
ference in frequency of the homozygous c.985A>G mu-
tation could be due to the increased detection of milder
biochemical phenotypes by newborn screening, with a
relatively low risk of developing clinical disease, and
associated to mutations found only in screened popula-
tions [4,31,36]. Notably, residual MCAD activity is sig-
nificantly lower in patients with the common mutation
(range 0-8%), compared to those with other variants
(range 0-63%) [22].
Although most reports indicate that patients homo-
zygous for the most common mutation have a poorer
outcome [2,37,38], some homozygous patients who
were asymptomatic until adulthood were also reported
[4,8,38,39].
The main goal of the present study was to evaluate
any relationships between biochemical findings at diag-
nosis, genotype, free carnitine (C0) levels during follow-




The present study population comprised MCADD pa-
tients diagnosed by two of the Spanish regional (Galicia
and western Andalusia) and one Portuguese (north/cen-
tral) NBS programs. From the initiation of newborn
screening by MS/MS in each region (in Galicia in 2000,
in Andalusia in 2009, and in Portugal in 2004) until
December 2011, the total number of MCADD cases
detected were, 13 in Galicia (incidence 1:18736), 8 in
Andalusia (incidence 1:23656) and 28 in north/central
Portugal (incidence 1:11799). Global frequency is
1:15575. Four cases lacking sufficient genetic or follow-
up data were excluded. The final ethnic breakdown was
31 Gypsy and 14 Caucasian patients.
At diagnosis, the following parameters were evaluated:
age at which analytical samples were taken for NBS,
presence or absence of clinical symptoms, C0, medium
chain acylcarnitines (C8, C6, C10, C10:1) and ratios of
C8/C2 and C8/C10 on the NBS blotter. Diagnosis was
confirmed by mutation analysis of the ACADM gene.
Clinical course was subsequently monitored.
During follow-up patients received a normal diet,
according to age and avoiding prolonged fasting and
lipolysis. A daily intake of 1-2 g/kg of slow absorption
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age. During any acute intercurrent illness the treatment
protocol was: careful management with frequent admi-
nistration of drinks containing an appropriate amount of
glucose until the patient improved. In case of vomiting or
clinical deterioration, an urgent hospital admission for
intravenous glucose infusion was recommended. Bio-
chemical follow-up included measurement of C0 in blood
spot/plasma at each visit (average frequency of 3 months)
and an annual determination of general biochemical pa-
rameters including transaminase levels. Few data exist on
the consequences of low carnitine in MCADD; supple-
mentation was prescribed if C0 fell below 12 μmol/L in
blood spots or below 20 μmol/L in plasma. Supplementa-
tion was only stopped after 2 independent determinations
showed free carnitine higher than μmol/L in blood spots
or 20 μmol/L in plasma. Carnitine was reintroduced if it
fell again below the control values.
Informed consent was obtained from the parents of all
patients. The study was approved by the Ethics Committee
of each Hospital. Institutional Review Board: Fundación
Ramón Dominguez G 15796683. Address: Travesía da




Acylcarnitines in blood spots were studied by the stand-
ard method of butylation and analysis by MS/MS.
MCADD was suspected in a newborn if the medium chain
acylcarnitines and/or C8/C2 or C8/C10 ratios were higher
than the 99.9th percentile of the specific medium
acylcarnitine (C8) and/or the ratios C8/C2 or C8/C10 (C8
p99.9 = 0.52 μM; C8/C2 p99.9 = 0.02; C8/C10 p99.9 = 1.8).
Molecular testing
DNA was isolated and sequenced by standard proce-
dures for blood samples of all patients and their parents,
except for two patients conceived by in vitro fertilization
with oocyte donation (Patients 1 and 16, Additional file
1), and whose biological mothers were not available for
analysis. Molecular analysis of ACADM was performed
using standard procedures. Primers were designed to
overlap the coding sequences and their flanking regions
(sequences available on request). PCR products were
purified by ExoSap (usb®) enzyme and sequenced using a
Big Dye Terminator Cycler Sequencing Ready reaction
kit and the manufacturer’s protocol (Applied Biosystems).
The sequencing reactions were performed in an ABI
3130XL Genetic Analyser.
Biochemical follow-up
C0 was evaluated in blood spots or plasma samples.
When using blood spots it was measured by MS/MS,according to the method of Zytkovicz et al [27]. In
plasma, C0 was measured by the classical enzymatic/
spectrophotometric assay [40].
When appropriate, data were statistically analyzed
using the Student’s t-test (with p < 0.05 taken to indicate
significance).
Results
During the study period we evaluated 45 patients with
MCADD detected by NBS, with the following geograph-
ical distribution: 26 cases from Portugal, 13 from Galicia,
and 6 from Andalusia. The average age of analytical
sample collection during screening was 7 days (range: 0-
35), with a median of 5 days and a mode of 4 days. In
82.2% cases samples were obtained during the first week
of life (37/45). In the remaining 8 cases (17.8%) repeat
samples were analyzed subsequently, due to invalidity of
the first sample. At diagnosis, all patients were asymptom-
atic with increased levels of medium chain acylcarnitines.
As shown in Additional file 1, all but patient 39 exhibited
a marked elevation of C8 (average 4.8 ± 4.1 μmol/L;
CV < 0.52). On the fourth day of postnatal age, patient
39 had a C8 value between percentiles 99.5 (0.37 μM)
and 99.9 (0.52 μM), but a higher than normal C8/C2 ra-
tio (0.04). A repeat sample, taken at 23 days of age
showed a slight increase in C8 (0.54 μM) and C8/C2
(0.05), justifying a genetic study. The C8/C2 ratio was
highly increased in all patients, with an average value of
0.28 ± 0.21 (CV < 0.02). A similar tendency was ob-
served with the C8/C10 ratio, with an average value of
9.8 ± 5.7 μmol/L (CV < 1.85), but in patients 35 and 39
this ratio was normal (C8/C10 = 1.6 and 1). On re-
sampling this ratio increased slightly (C8/C10 = 1.81).
Increased levels of C10 or C10:1 was seen in nineteen
and thirty nine patients respectively.
A diagnosis of MCADD was confirmed by molecular
testing in all patients; 34 patients were homozygous for
the prevalent c.985A>G (p.Lys329Glu) mutation and 10
patients were compound heterozygous for the prevalent
and another mutation. Only patient 45 did not carry the
c.985A>G mutation in any of the alleles (Additional file 1).
Three of the mutations detected, c.600G>T (p.Trp200Cys),
c.245G>C (p.Trp82Ser) and c.542A>G (p.Asp181Gly), are
novel. Among our screened cases the prevalence of the
common mutation was 86% (78 out of 90 alleles).
Levels of C8 and ratios of C8/C10 and C8/C2 were sig-
nificantly higher (p = 0.016), while C0 was significantly
lower (p < 0.001) in patients who were homozygous for
the prevalent c.985A>G mutation, compared to with those
with other genotypes (Additional file 1).
After diagnosis, all patients received dietary recommen-
dations, but supplementation with L-carnitine (20-60 mg/
kg/day) was prescribed only to thirty-two patients, having
a low C0.
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(range 2 months-10 years 7 months). Follow-up data were
available in 39 out of 45 cases (28 homozygous for the
c.985A>G mutation and 11 with other genotypes). Eighty-
two percent of patients (32/39) were given carnitine
supplementation. Carnitine was not administered to 6 pa-
tients as their levels were consistently within the control
range. One patient did not receive supplementation be-
cause his parents declined treatment, despite fulfilling the
biochemical indication as per our protocol. Following car-
nitine treatment, the average C0 levels were significantly
lower in patients homozygous for the common muta-
tion than in patients with other mutations (14 μmol/L vs
22 μmol/L, p < 0.001) (Additional file 1). Among the 28
cases homozygous for the c.985A>G mutation, 26 (92.8%)
required L-carnitine supplementation to reach normal
levels, while fewer patients with other genotypes needed
supplementation (6/11; 54.5%). The average follow-up
period for homozygous patients was 31 months while the
average for other patients was 18 months. According to
our protocol, carnitine supplementation could never be
stopped in eleven homozygous patients (34.3%). Supple-
mentation was stopped in 15 homozygous patients but,
reintroduction was necessary in 11 patients. Among 11
patients with a genotype other than homozygosity for the
common mutation, carnitine supplementation was only
required in one of them continuously (9.1%).
Two patients of Gypsy ethnicity (patients 4 and 33;
Additional file 1) died at 15 and 32 months of age, re-
spectively. Despite frequent carnitine supplementation,
patient 4 consistently showed low C0 levels (average 10
μM). This patient died in a hospital not participating in
the study, due to a lower respiratory tract infection. Pa-
tient 33 frequently showed low C0 levels (average 11.5
μM), but supplementation of carnitine was not always
complied with. This patient died after presenting with
gastroenteritis, decreased consciousness, hypotonia and
in cardiorespiratory arrest.
Another three (patients 13, 17 and 21, Additional file 1),
also of Gypsy ethnicity, suffered metabolic crises with epi-
sodes of hypoglycaemia and vomiting, triggered by infec-
tion. The remaining patients never had a metabolic crisis,
although one (patient 31, Additional file 1) was also diag-
nosed with maple syrup urine disease.
Discussion
C8 levels and several other ratios are utilized in screening
for MCADD. We analysed the C8, C8/C2 and C8/C10 in
our study and found C8/C2 ratio to be more accurate than
either C8 and C8/C10, as it was elevated in all patients. By
comparison, C8 was elevated in 44/45 and C8/C10 in 43/
45 patients. We therefore consider the calculation of C8/
C2 ration very important in screening for MCADD. This
was exemplified in patients 35 and 39 whose diagnosiscould easily have been missed without referral to the C8/
C2 ratio. Both these patients were compound heterozy-
gous for the common c.985A>G mutation as well as for
other reported pathogenic mutations (c.683C>A [41] and
c.199T>C [3]), respectively. It is thought that these latter
two mutations might confer a more attenuated biochem-
ical phenotype [3,41]. Patient 39 presented a biochemical
profile similar to MCAD carrier, as also described Hsu
et al. [42], and never showed clinical signs. The percentage
of cases homozygous for the common mutation (76%)
detected in our cohort was higher than previously
reported, ranging from 30% to 71% (47.4% [3]; 43% [4];
53% [19]; 61% [21]; 37% [27]; 71% [30]; 40% [31]; 63%
[32]; 36.4% [33]; 52% [34]; 30% [35]). Our results could
have a bias due to the high proportion of patients of
Gypsy ethnicity (31/45, 69%), in whom the common allele
shows a high population frequency [43]; 22/26 (84.6%) of
our patients from Portugal were homozygous for the com-
mon mutation, while the remaining 12 homozygous pa-
tients were from Spain. We have previously observed that
the prevalence for the common mutation in patients from
Galicia (north-west Spain) was also high, at 63% [24].
The higher plasma C8 levels and C8/C10 and C8/C2
ratios that we have found in patients homozygous for
the c.985A>G mutation agree with previous reports
[3,4,20,23,24,34,38,44]. We noted a statistically signifi-
cant association between low C0 level at NBS and
homozygosity. As shown in Additional file 1, patients
homozygous for the common mutation tended to main-
tain lower levels of C0 and carnitine supplementation is
more frequent necessary in order that the plasma carni-
tine levels remain within the normal range. Treatment
for MCADD is based mainly on diet: avoidance of
fasting and ensuring high carbohydrate intake during ill-
ness. L-carnitine treatment has been proposed in
MCADD therapy [45], although there is as yet no good
evidence to support this recommendation. A survey of
thirty-one centers in Europe, North America, Asia and
Australia showed L-carnitine supplementation in MCADD
to be controversial: 36% of the centers routinely used oral
carnitine whereas 32% used it only in cases of proven carni-
tine deficiency or intercurrent infection [46]. Bzduch et al
[47] reported a homozygous patient who had suffered two
Reye-like episodes and whose C0 decreased continuously
from an acute crisis for a further 8-13 days but then
returned to normal by the 25th day after the episode.
Apart from the c.985A>G mutation, it is well docu-
mented that most of the ACADM mutations seen in
MCADD patients who have been diagnosed as a result
of NBS are associated with asymptomatic or moderate
clinical forms [48] of the disease. While it is also known
that patients with these less commonly seen ACADM
genotypes are also at risk of metabolic decompensation
during periods of illness or metabolic stress [7,43,49,50],
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11% of patients (5/45), all of whom were homozygous
for the c.985A>G mutation.
In conclusion, our study points to that the ACADM
genotype most commonly seen in MCADD might be of
particular relevance in refining a follow-up protocol,
since plasma carnitine levels in patients homozygous for
c.985A>G tend to be lower and supplementation is re-
quired to maintain carnitine within the normal range.
Nevertheless, this associations needs to be further sup-
ported by future studies with larger patients cohorts.
Our results suggest that dietary management should be
complemented with close monitoring of C0 levels and
carnitine should be supplemented when necessary, and
point to that this might be of particularly importance in
patients homozygous for the common mutation. By
demonstrating an association between carnitine levels
and homozygosity for the c.985A>G mutation, the cur-
rent study also contributes to our understanding of the
relationship between genotype/biochemical markers and
phenotype in MCADD. To a large extent, however,
MCAD deficiency remains unpredictable, indicating the
need for further prospective studies.
Additional file
Additional file 1: Table S1. Summary of levels of acylcarnitines at
diagnosis, mutations, carnitine free levels, treatment and evolution of
MCADD patients.
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